4 recruiting, 2 completed, 1 terminated, 1 unknown. 8 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 4, Completed 2, Terminated 1, Unknown 1 |
| Phase 1 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow HIV I Infection: new trials by email Literature Review of HIV I Infection trials Research Report on HIV I Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals Maraviroc, Dolutegravir, Dendritic Cell Vaccine - Hiv, HIV I Infection | Phase 2 | Recruiting | Federal University of São Paulo | 70 | 2026-07-15 | 2026-08-19 |
| Studying Topiramate for Re-Activating the HIV-1 Reservoir Topiramate - HIV-1-infection, Hiv | Phase 1 / Phase 2 | Unknown | Erasmus Medical Center | 12 | 2024-09-01 | 2024-02-28 |
| Evaluating the Safety and Immunogenicity of MTBVAC MTBVAC, BCG - HIV I Infection, Tuberculosis | Phase 2 | Recruiting | HIV Vaccine Trials Network | 276 | 2024-01-30 | 2026-10-30 |
| Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy Estradiol - HIV I Infection | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 93 | 2024-01-04 | 2026-04-08 |
| Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis Adalimumab Injection - Tuberculous Meningitis, HIV I Infection | Phase 2 | Recruiting | ANRS, Emerging Infectious Diseases | 130 | 2023-04-11 | 2025-12-15 |
| Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy Nivolumab 10 MG/ML [Opdivo], Saline - HIV I Infection | Phase 1 / Phase 2 | Recruiting | University of Melbourne | 42 | 2023-01-24 | 2025-12-22 |
| Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir Romidepsin, Vacc-4x, rhuGM-CSF - HIV I Infection | Phase 1 / Phase 2 | Completed | Bionor Immuno AS | 26 | 2014-03-01 | 2017-03-01 |
| Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV Vacc-4x, Sterile water - HIV I Infection | Phase 2 | Completed | Bionor Immuno AS | 137 | 2008-08-01 | 2017-02-23 |
Acquired Immunodeficiency Syndrome (2) · HIV Infections (1) · Shock (1) · Tuberculosis (1) · Tuberculosis, Meningeal (1)
Infections (4) · Actinomycetales Infections (2) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2) · Gram-Positive Bacterial Infections (2) · Immune System Diseases (2) · Immunologic Deficiency Syndromes (2) · Lentivirus Infections (2) · Mycobacterium Infections (2) · RNA Virus Infections (2) · Retroviridae Infections (2) · Sexually Transmitted Diseases (2)
Vacc-4x (2) · Adalimumab (1) · Auranofin (1) · Estradiol (1) · MTBVAC vaccine (1) · Maraviroc (1) · Niacinamide (1) · Nivolumab (1) · Sodium Chloride (1) · Topiramate (1) · dolutegravir (1) · lentiviral minigene vaccine of COVID-19 coronavirus (1) · romidepsin (1) · sargramostim (1)
Bionor Immuno AS (2) · ANRS, Emerging Infectious Diseases (1) · Erasmus Medical Center (1) · Federal University of São Paulo (1) · HIV Vaccine Trials Network (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Melbourne (1)
Brazil (2) · United States (2) · Australia (1) · Denmark (1) · Germany (1) · Italy (1) · Mexico (1) · Mozambique (1) · Netherlands (1) · Peru (1) · Singapore (1) · South Africa (1) · Spain (1) · Thailand (1) · United Kingdom (1)
Jordan E. Lake, MD, MSc (1) · Jorge A. Gallardo-Cartagena, MD (1) · Kimberly K. Scarsi, PharmD, MS, FCCP (1) · Limakatso Lebina (1) · Mark Hatherill (1) · Richard Pollard, MD (1) · Sharon Lewin (1)